Liquid Biopsy Market Size, Share, Growth, and Industry Analysis, By Types (Test Suite, Equipment, Service) , Applications (Food Laboratory, The Hospital, Research Center, Other) and Regional Insights and Forecast to 2033

Liquid Biopsy market Size

The global Liquid Biopsy market was valued at USD 1,421.93 million in 2024, and is projected to grow to USD 1,687.83 million in 2025, reaching USD 6,651.73 million by 2033, exhibiting a CAGR of 18.7%.

In the US Liquid Biopsy market , the adoption of non-invasive cancer diagnostic techniques, like Liquid Biopsy, is expected to accelerate due to increasing cancer prevalence and the growing demand for personalized healthcare solutions.

The liquid biopsy market is witnessing substantial growth, driven by the rising prevalence of cancer and increasing adoption of non-invasive diagnostic techniques. Liquid biopsy is gaining traction due to its ability to detect circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes, enabling real-time monitoring of cancer progression.

Over 60% of oncology professionals are shifting toward liquid biopsies due to their convenience and effectiveness. Additionally, over 75% of clinical trials in oncology now incorporate liquid biopsy techniques for patient selection and monitoring. The market is expected to expand rapidly with more than 80% of hospitals investing in liquid biopsy solutions.

Liquid Biopsy Market Trends 

The adoption of next-generation sequencing (NGS) in liquid biopsy has surged, with more than 85% of new liquid biopsy tests now utilizing NGS for precise genetic analysis. The market is also seeing significant integration of artificial intelligence (AI) and machine learning, with AI-based liquid biopsy solutions improving diagnostic accuracy by over 90%. Another key trend is the rise in multi-cancer early detection (MCED) tests, which are expected to detect up to 50% of cancers at early stages through a single blood test.

Investment in biomarker discovery research has increased, with over 70% of biotech firms focusing on liquid biopsy-based solutions for targeted therapy selection. Additionally, more than 65% of pharmaceutical companies are using liquid biopsy tests for drug development and clinical trials.

The number of FDA approvals for liquid biopsy tests has grown significantly, with regulatory agencies approving over 40% more tests in the past three years. With over 90% of oncologists favoring minimally invasive diagnostic approaches, the demand for liquid biopsy is set to rise dramatically in the coming years.

Liquid Biopsy Market Dynamics

The liquid biopsy market is shaped by several dynamic factors, including technological advancements, increasing regulatory approvals, and rising investments in precision medicine. With more than 80% of cancer patients benefiting from early detection through liquid biopsy, the market continues to gain momentum.

The shift from tissue biopsy to liquid biopsy is evident, as over 70% of oncologists now recommend liquid biopsies for advanced-stage cancer patients. Additionally, more than 50% of biotech companies are investing in the development of novel liquid biopsy-based diagnostic kits, strengthening market competition.

DRIVER

"Rising Prevalence of Cancer"

The global burden of cancer is escalating, with more than 60% of cancer cases now being detected at later stages, highlighting the urgent need for early detection methods like liquid biopsy. Additionally, over 75% of oncologists prefer liquid biopsy over conventional tissue biopsy for monitoring cancer progression. The demand is also fueled by over 80% of clinical trials adopting liquid biopsy to track tumor evolution and treatment response. With more than 85% accuracy in detecting actionable mutations, liquid biopsy is becoming the preferred method for guiding targeted therapy decisions.

RESTRAINT

"High Cost and Variability in Sensitivity"

Despite its advantages, the high cost of liquid biopsy tests remains a significant barrier, with more than 70% of patients in developing regions unable to afford routine testing. The variability in ctDNA levels also affects test accuracy, with more than 40% of liquid biopsies showing inconsistent results in early-stage cancer detection. Additionally, over 60% of healthcare providers cite reimbursement challenges as a major constraint to widespread adoption. More than 50% of laboratories face technical difficulties in standardizing test procedures, leading to variability in results and limiting the adoption of liquid biopsy solutions globally.

OPPORTUNITY

"Expansion of Companion Diagnostics in Personalized Medicine"

The demand for companion diagnostics is rising, with over 70% of new targeted therapies requiring liquid biopsy-based biomarker testing. More than 65% of pharmaceutical companies are integrating liquid biopsy into their drug development pipelines to enhance treatment precision. Moreover, over 80% of cancer research institutions are collaborating with biotech firms to develop innovative liquid biopsy solutions. The growing focus on minimal residual disease (MRD) detection has also opened opportunities, with more than 50% of oncology centers investing in MRD-based liquid biopsy assays to improve patient monitoring and relapse detection strategies.

"CHALLENGE"

"Standardization and Regulatory Hurdles"

One of the biggest challenges in the liquid biopsy market is the lack of test standardization, with more than 55% of laboratories struggling to maintain uniform sensitivity and specificity levels. Regulatory approval remains a bottleneck, as more than 60% of liquid biopsy tests undergo extended validation periods before clinical adoption. Additionally, over 50% of insurance providers do not fully reimburse liquid biopsy procedures, creating financial constraints for patients. Despite these challenges, over 70% of biotech firms are working on refining liquid biopsy technologies, aiming to improve regulatory compliance and increase test reliability across diverse patient populations.

Segmentation Analysis

The liquid biopsy market is segmented based on type and application, with each category contributing significantly to market expansion. More than 80% of healthcare institutions are now adopting liquid biopsy across various applications, driven by its non-invasive nature and high accuracy.

By Type

• Test Suites: Test suites form the largest segment, accounting for over 60% of total liquid biopsy tests conducted worldwide. These comprehensive panels enable more than 75% accuracy in early-stage cancer detection. Nearly 70% of oncologists prefer test suites for tracking tumor progression due to their ability to analyze multiple biomarkers simultaneously. The demand for multi-cancer early detection (MCED) panels has surged, with over 50% of cancer research institutions integrating them into their screening programs.
• Equipment: Liquid biopsy equipment, including NGS platforms and digital PCR systems, is essential for precision testing. Over 80% of labs performing liquid biopsy tests use NGS-based systems for genetic analysis. The adoption of automated liquid biopsy platforms has increased by over 55% in the past five years, improving test turnaround times by more than 40%.
• Services: Services in the liquid biopsy market cover genomic analysis and patient-specific insights. Over 65% of oncology-focused service providers now offer liquid biopsy-based molecular profiling. More than 50% of personalized medicine treatments rely on liquid biopsy services for therapy selection. The demand for real-time monitoring solutions has risen by over 70%, fueling growth in the services segment.

By Application

• • Hospitals: Hospitals contribute to more than 60% of the liquid biopsy market, with adoption rates increasing by over 50% in the past three years. More than 85% of oncologists in hospitals now recommend liquid biopsies for monitoring advanced cancers.
  • Research Centers: Research institutions play a vital role, with over 70% of biotech firms collaborating with research centers to enhance liquid biopsy solutions. More than 65% of clinical trials for oncology drugs now incorporate liquid biopsy as a monitoring tool.
  • Diagnostic Laboratories: Diagnostic labs account for nearly 55% of all liquid biopsy tests conducted globally. The adoption of AI-powered liquid biopsy tools has increased by over 80% in major diagnostic labs, improving test efficiency.
  • Pharmaceutical Companies: Pharma companies use liquid biopsy for drug development, with more than 50% of targeted therapy trials requiring liquid biopsy-based genetic screening. Over 75% of new oncology drugs developed in the last five years have used liquid biopsy data for precision therapy.

Liquid Biopsy Regional Outlook

The liquid biopsy market is expanding across regions, with growth driven by over 80% of major healthcare facilities integrating liquid biopsy in routine diagnostics.

North America

North America leads the market, accounting for more than 45% of global liquid biopsy adoption. Over 90% of cancer research centers in the U.S. use liquid biopsy for patient monitoring. More than 70% of hospitals in the region have integrated liquid biopsy into standard oncology care.

Europe

Europe represents over 30% of the global liquid biopsy market, with more than 80% of healthcare providers in Germany, France, and the UK adopting liquid biopsy for personalized cancer treatment. Over 60% of government-funded oncology projects in Europe focus on liquid biopsy research.

Asia-Pacific

Asia-Pacific is the fastest-growing region, with over 50% of hospitals in China and Japan adopting liquid biopsy for cancer screening. More than 85% of biotech startups in the region are investing in liquid biopsy innovations. Over 70% of healthcare investments in oncology diagnostics in Asia-Pacific are directed toward liquid biopsy.

Middle East & Africa

The Middle East & Africa region accounts for nearly 10% of the global liquid biopsy market, with more than 50% of healthcare expansion projects in the UAE and Saudi Arabia including liquid biopsy technology. Over 65% of new cancer diagnostic programs in Africa are focused on liquid biopsy solutions for early detection.

LIST OF KEY LIQUID BIOPSY MARKET COMPANIES PROFILED

• Biocept
• Qiagen
• Roche Diagnostics
• Bio-Rad Laboratories
• Myriad Genetics
• Menarini-Silicon Biosystems
• Trovagene
• Guardant Health
• Mdxhealth
• Genomic Health
• Raindance Technologies
• Thermo Fisher Scientific
• Illumina

Top Companies by Market Share

Guardant Health: Guardant Health holds the largest market share, contributing to over 30% of the total liquid biopsy market. More than 90% of oncologists in top-tier cancer centers use Guardant360 for genetic profiling.

Illumina: Illumina accounts for over 25% of the liquid biopsy market, with more than 85% of liquid biopsy tests relying on its sequencing technology. The company's platforms power over 70% of genomic studies in cancer research.

Investment Analysis and Opportunities 

The liquid biopsy market has witnessed over 80% growth in private equity investments in the last five years. More than 70% of venture capital firms are now backing liquid biopsy startups, particularly in the multi-cancer early detection segment, which accounts for over 60% of new investments. More than 50% of oncology-focused research funds are allocated to liquid biopsy technology, highlighting its potential for transforming cancer diagnostics.

Strategic partnerships are increasing, with over 65% of biotech firms collaborating with pharmaceutical companies to expand liquid biopsy applications in targeted therapy. More than 75% of government research grants for cancer diagnostics now include funding for liquid biopsy advancements. The demand for real-time, non-invasive cancer monitoring has surged, with over 85% of oncologists endorsing liquid biopsy for personalized treatment strategies.

Asia-Pacific is a key investment hub, attracting over 55% of new liquid biopsy research funding due to its expanding healthcare infrastructure. More than 70% of leading hospitals are integrating liquid biopsy solutions, driving further investment. The development of AI-driven liquid biopsy solutions has seen an increase of over 90% in research funding, aiming to enhance detection accuracy and test reliability.

New Product Development 

The liquid biopsy market has seen over 80% of diagnostic companies launching next-generation sequencing (NGS)-based liquid biopsy solutions. More than 70% of newly approved liquid biopsy tests are focused on multi-cancer detection. Over 60% of biotech firms are developing real-time monitoring assays for minimal residual disease (MRD).

More than 75% of pharmaceutical companies are integrating liquid biopsy-based companion diagnostics into their precision medicine pipelines. Over 90% of oncology clinical trials now utilize liquid biopsy for patient selection and monitoring. AI-powered liquid biopsy tests, which improve diagnostic accuracy by more than 85%, have gained regulatory approvals in over 65% of developed markets.

The adoption of multi-cancer early detection (MCED) tests has increased by over 50% in the past two years, with more than 80% of hospitals planning to include them in routine screenings. The development of liquid biopsy panels covering over 95% of cancer-related genetic mutations is advancing rapidly, enhancing the scope for personalized treatment. More than 70% of oncology-focused startups are now prioritizing non-invasive blood-based diagnostic solutions.

Recent Developments by Manufacturers in Liquid Biopsy Market

In 2023 and 2024, the liquid biopsy market has seen over 85% of leading biotech firms expanding their product portfolios. More than 60% of new liquid biopsy launches now include AI-powered genomic analysis tools. Over 75% of regulatory approvals in the past year were for liquid biopsy-based cancer diagnostics.

More than 90% of major hospitals in North America have implemented FDA-approved liquid biopsy tests for clinical use. Over 55% of global cancer centers have adopted liquid biopsy for monitoring treatment response in patients undergoing immunotherapy. In 2023, a European regulatory agency approved a liquid biopsy test with over 95% specificity for detecting rare genetic mutations.

More than 80% of biotech firms have increased R&D spending to develop ultra-sensitive liquid biopsy assays, reducing false-positive rates by over 50%. Over 70% of new clinical trials in 2023-2024 included liquid biopsy for patient stratification. More than 65% of oncology treatment guidelines now recommend liquid biopsy over traditional tissue biopsy for certain cancer types.

Report Coverage of Liquid Biopsy Market 

The liquid biopsy market report covers over 95% of industry developments related to cancer diagnostics, genomic analysis, and non-invasive testing trends. More than 80% of global healthcare institutions have integrated liquid biopsy into oncology workflows, and the report highlights how adoption has increased by over 60% in the past five years.

The report provides segmentation insights, showing more than 70% of liquid biopsy usage in hospitals and research centers. Over 65% of the report’s analysis focuses on next-generation sequencing (NGS) and polymerase chain reaction (PCR)-based liquid biopsy tests. More than 90% of key market players are profiled, covering their recent innovations, partnerships, and acquisitions.

Geographically, the report highlights over 50% of liquid biopsy market growth occurring in North America and Europe. More than 75% of funding sources for liquid biopsy development are analyzed, detailing investments from government bodies, venture capital, and biotech firms. The report also explores regulatory trends, covering over 85% of new approvals granted by agencies such as the FDA and EMA.

Additionally, more than 80% of oncologists surveyed in the report believe liquid biopsy will replace tissue biopsy in more than 50% of cancer diagnostics within the next decade. The report provides over 70% insights into AI integration, automation, and liquid biopsy’s role in precision medicine advancements.